These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. Li D; Chen T; Hu Y; Zhou Y; Liu Q; Zhou D; Jin X; Huang Z J Virol; 2016 Oct; 90(19):8720-8. PubMed ID: 27440895 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists. Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243 [TBL] [Abstract][Full Text] [Related]
6. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies. Ye L; Lin J; Sun Y; Bennouna S; Lo M; Wu Q; Bu Z; Pulendran B; Compans RW; Yang C Virology; 2006 Aug; 351(2):260-70. PubMed ID: 16678231 [TBL] [Abstract][Full Text] [Related]
7. Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection. Okumura A; Rasmussen AL; Halfmann P; Feldmann F; Yoshimura A; Feldmann H; Kawaoka Y; Harty RN; Katze MG J Virol; 2015 Oct; 89(20):10399-406. PubMed ID: 26246577 [TBL] [Abstract][Full Text] [Related]
9. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. Licata JM; Johnson RF; Han Z; Harty RN J Virol; 2004 Jul; 78(14):7344-51. PubMed ID: 15220407 [TBL] [Abstract][Full Text] [Related]
10. Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection. Veljkovic V; Loiseau PM; Figadere B; Glisic S; Veljkovic N; Perovic VR; Cavanaugh DP; Branch DR F1000Res; 2015; 4():34. PubMed ID: 25717373 [TBL] [Abstract][Full Text] [Related]
11. Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction. Pleet ML; Mathiesen A; DeMarino C; Akpamagbo YA; Barclay RA; Schwab A; Iordanskiy S; Sampey GC; Lepene B; Nekhai S; Aman MJ; Kashanchi F Front Microbiol; 2016; 7():1765. PubMed ID: 27872619 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Ebola Virus Inhibitors for Drug Repurposing. Madrid PB; Panchal RG; Warren TK; Shurtleff AC; Endsley AN; Green CE; Kolokoltsov A; Davey R; Manger ID; Gilfillan L; Bavari S; Tanga MJ ACS Infect Dis; 2015 Jul; 1(7):317-26. PubMed ID: 27622822 [TBL] [Abstract][Full Text] [Related]
13. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. Yonezawa A; Cavrois M; Greene WC J Virol; 2005 Jan; 79(2):918-26. PubMed ID: 15613320 [TBL] [Abstract][Full Text] [Related]
14. Possible FDA-approved drugs to treat Ebola virus infection. Yuan S Infect Dis Poverty; 2015; 4():23. PubMed ID: 25984303 [TBL] [Abstract][Full Text] [Related]
15. Analysis of Ebola virus and VLP release using an immunocapture assay. Kallstrom G; Warfield KL; Swenson DL; Mort S; Panchal RG; Ruthel G; Bavari S; Aman MJ J Virol Methods; 2005 Jul; 127(1):1-9. PubMed ID: 15893559 [TBL] [Abstract][Full Text] [Related]
16. Novel Small Molecule Entry Inhibitors of Ebola Virus. Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510 [TBL] [Abstract][Full Text] [Related]
17. Repurposing potential of 1st generation H Schafer A; Cheng H; Xiong R; Soloveva V; Retterer C; Mo F; Bavari S; Thatcher G; Rong L Antiviral Res; 2018 Sep; 157():47-56. PubMed ID: 29981374 [TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Chen CZ; Shinn P; Itkin Z; Eastman RT; Bostwick R; Rasmussen L; Huang R; Shen M; Hu X; Wilson KM; Brooks B; Guo H; Zhao T; Klump-Thomas C; Simeonov A; Michael SG; Lo DC; Hall MD; Zheng W bioRxiv; 2020 Aug; ():. PubMed ID: 32839771 [TBL] [Abstract][Full Text] [Related]
19. ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress. Han Z; Madara JJ; Liu Y; Liu W; Ruthel G; Freedman BD; Harty RN J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S138-45. PubMed ID: 25786915 [TBL] [Abstract][Full Text] [Related]
20. Host Cell Plasma Membrane Phosphatidylserine Regulates the Assembly and Budding of Ebola Virus. Adu-Gyamfi E; Johnson KA; Fraser ME; Scott JL; Soni SP; Jones KR; Digman MA; Gratton E; Tessier CR; Stahelin RV J Virol; 2015 Sep; 89(18):9440-53. PubMed ID: 26136573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]